secwatch.observer — SEC 8-K summary
======================================

Issuer:     SCYNEXIS INC (SCYX)
CIK:        0001178253
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0001564590-22-009487
Event type: debt
Sentiment:  neutral
Materiality: 0.40
Item codes: 2.03
LLM model:  deepseek-v4-flash:cloud@v2

SCYNEXIS receives $5M third tranche from Hercules/SVB Term Loan after CANDLE milestone
--------------------------------------------------------------------------------

- On March 9, 2022, SCYNEXIS drew $5M under its existing $60M Term Loan with Hercules/SVB.
- The tranche was triggered by positive Phase 3 CANDLE study results for ibrexafungerp.
- Prior draws: $20M at closing (May 2021), $10M on FDA approval (June 2021).
- Total drawn now $35M; remaining tranches subject to conditions.
- Loan facility provided by Hercules Capital and Silicon Valley Bank.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178253/000156459022009487/0001564590-22-009487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178253/000156459022009487/scyx-8k_20220309.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-009487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer